Cargando…

Novel insight into histological and molecular astrocytoma, IDH‐mutant, Grade 4 by the updated WHO classification of central nervous system tumors

BACKGROUND: The latest fifth edition of the World Health Organization (WHO) classification of the central nervous system (CNS) tumors (WHO CNS 5 classification) released in 2021 defined astrocytoma, IDH‐mutant, Grade 4. However, the understanding of this subtype is still limited. We conducted this s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Wenlin, Guo, Siying, Wang, Yaning, Shi, Yixin, Guo, Xiaopeng, Liu, Delin, Li, Yilin, Wang, Yuekun, Xing, Hao, Xia, Yu, Li, Junlin, Wu, Jiaming, Liang, Tingyu, Wang, Hai, Liu, Qianshu, Jin, Shanmu, Qu, Tian, Li, Huanzhang, Yang, Tianrui, Zhang, Kun, Wang, Yu, Ma, Wenbin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557904/ https://www.ncbi.nlm.nih.gov/pubmed/37667984 http://dx.doi.org/10.1002/cam4.6476

Ejemplares similares

Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumors
por: Guo, Xiaopeng, et al.
Publicado: (2023)

Spotlights on adult patients with pediatric-type diffuse gliomas in accordance with the 2021 WHO classification of CNS tumors
por: Chen, Wenlin, et al.
Publicado: (2023)

Clinical updates on gliomas and implications of the 5th edition of the WHO classification of central nervous system tumors
por: Guo, Xiaopeng, et al.
Publicado: (2023)

An online survival predictor in glioma patients using machine learning based on WHO CNS5 data
por: Ye, Liguo, et al.
Publicado: (2023)

Characteristic analysis and identification of novel molecular biomarkers in elderly glioblastoma patients using the 2021 WHO Classification of Central Nervous System Tumors
por: Wang, Yaning, et al.
Publicado: (2023)

Molecular landscape of IDH-mutant astrocytoma and oligodendroglioma grade 2 indicate tumor purity as an underlying genomic factor
por: Zhao, Binghao, et al.
Publicado: (2022)

Palliative care for patients with glioma: A recent scientometric analysis of the Web of Science in 2022
por: Xiao, Zhiyuan, et al.
Publicado: (2022)

Prognostic Value of Choline and Other Metabolites Measured Using (1)H-Magnetic Resonance Spectroscopy in Gliomas: A Meta-Analysis and Systemic Review
por: Shi, Yixin, et al.
Publicado: (2022)

Recent advances and future challenges of tumor vaccination therapy for recurrent glioblastoma
por: Zhao, Binghao, et al.
Publicado: (2023)

Tumor-Treating Fields in Glioblastomas: Past, Present, and Future
por: Guo, Xiaopeng, et al.
Publicado: (2022)

Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy
por: Zhao, Binghao, et al.
Publicado: (2022)

Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients
por: Wang, Zihao, et al.
Publicado: (2021)

Comprehensive ability evaluation and trend analysis of patients with malignant intracranial tumors in the perisurgery period
por: Wang, Yaning, et al.
Publicado: (2021)

Prognostic Prediction Model for Glioblastoma: A Metabolic Gene Signature and Independent External Validation
por: Lei, Chuxiang, et al.
Publicado: (2021)

Multiple brain abscesses caused by Nocardia asiatica: Case report and literature review
por: Jin, Shanmu, et al.
Publicado: (2023)

Current evidence and challenges of systematic therapies for adult recurrent glioblastoma: Results from clinical trials
por: Chen, Wenlin, et al.
Publicado: (2021)

Rare Cases of IDH1 Mutations in Spinal Cord Astrocytomas
por: Konovalov, N. A., et al.
Publicado: (2020)

Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis
por: Lee, Kwanghoon, et al.
Publicado: (2023)

Clinical strategies to manage adult glioblastoma patients without MGMT hypermethylation
por: Liu, Delin, et al.
Publicado: (2022)

Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience
por: Cho, Uiju, et al.
Publicado: (2021)

Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of multivariable survival analyses
por: Zhao, Binghao, et al.
Publicado: (2020)

Imposing Phase II and Phase III Clinical Trials of Targeted Drugs for Glioblastoma: Current Status and Progress
por: Wang, Yaning, et al.
Publicado: (2021)

Grading of IDH-mutant astrocytoma using diffusion, susceptibility and perfusion-weighted imaging
por: Yang, Xiefeng, et al.
Publicado: (2022)

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

Cytomegalovirus and Glioblastoma: A Review of the Biological Associations and Therapeutic Strategies
por: Yang, Tianrui, et al.
Publicado: (2022)

Protocol to establish a genetically engineered mouse model of IDH1-mutant astrocytoma
por: Shi, Diana D., et al.
Publicado: (2023)

Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma
por: Sabunga, Olivia Desty, et al.
Publicado: (2022)

Global DNA methylation profiling reveals chromosomal instability in IDH-mutant astrocytomas
por: Liu, Yan, et al.
Publicado: (2022)

LOX Expression and Functional Analysis in Astrocytomas and Impact of IDH1 Mutation
por: da Silva, Roseli, et al.
Publicado: (2015)

Computational Analysis of IDH1, IDH2, and TP53 Mutations in Low-Grade Gliomas Including Oligodendrogliomas and Astrocytomas
por: Bendahou, Mohammed Amine, et al.
Publicado: (2020)

Optimal Therapies for Recurrent Glioblastoma: A Bayesian Network Meta-Analysis
por: Chen, Wenlin, et al.
Publicado: (2021)

The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas
por: Christians, Arne, et al.
Publicado: (2019)

LGG-45. A REPORT OF IDH-MUTANT BRAINSTEM ASTROCYTOMAS IN YOUNG ADULTS
por: Chang, Ellen, et al.
Publicado: (2020)

The prognostic impact of subclonal IDH1 mutation in grade 2–4 astrocytomas
por: Vij, Meenakshi, et al.
Publicado: (2023)

Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting
por: Rautajoki, Kirsi J., et al.
Publicado: (2023)

Investigation of Genetic Determinants of Glioma Immune Phenotype by Integrative Immunogenomic Scale Analysis
por: Zhao, Binghao, et al.
Publicado: (2021)

Immuno-phenotyping of IDH-mutant grade 3 astrocytoma and IDH-wildtype glioblastoma reveals specific differences in cells of myeloid origin
por: Raghavan, Jayashree V., et al.
Publicado: (2021)

Single-cell transcriptomic analyses provide insights into the cellular origins and drivers of brain metastasis from lung adenocarcinoma
por: Wang, Zihao, et al.
Publicado: (2023)

Prognostic Prediction Model for Glioblastoma: A Ferroptosis-Related Gene Prediction Model and Independent External Validation
por: Chen, Wenlin, et al.
Publicado: (2023)

Polysialic acid is associated with better prognosis and IDH1-mutation in diffusely infiltrating astrocytomas
por: Mäkelä, Katri, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qe5rrhaqe98hvjhktk8tjvdm77